Objective
The aim of this study was to evaluate left ventricular diastolic function parameters as an early predictor of cardiac involvement in patients with rheumatoid arthritis (RA) without any evidence of hypertension, diabetes mellitus, rheumatic fever or underlying cardiac disease, detected by Doppler echocardiography and to correlate diastolic function in RA patients with different RA disease characteristics.

Patients and methods
Seventy-five RA patients were diagnosed according to the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for RA and another 38 age-matched and sex-matched healthy participants were included. All patients and the control groups were submitted to M-mode, two-dimensional, Doppler (continuous and pulsed wave) echocardiography. Diastolic dysfunction was defined as when transmitral flow E/A ratio is less than one.

Results
Left ventricular diastolic dysfunction was found in 28 (37.3%) of 75 RA patients and four (10.5%) of 38 controls with a $P$ value of less than 0.05. In the patients’ group, a statistically significant correlation was found between diastolic dysfunction and duration of the disease ($P<0.05$), and disease activity was assessed by 28 Joint Disease Activity Score ($P<0.05$).

Conclusion
Among those without a history of cardiac disease, patients with RA have a higher prevalence of diastolic dysfunction than those without RA. Diastolic dysfunction in RA was associated with disease duration and disease activity. Thus, early identification of diastolic dysfunction in asymptomatic RA patients by the use of echocardiography may provide an opportunity to manage the underlying etiology to prevent progression to diastolic heart failure.

Keywords:
diastolic dysfunction, echocardiography, rheumatoid arthritis

Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and deterioration of the joints, which can produce a loss of functionality, reduces quality of life, and enhances morbidity and mortality [1]. The disease course varies greatly between patients; some patients have a mild disease course although in the majority of patients, the disease leads to progressive joint destruction and disability. Besides articular symptoms, RA can be associated with extra-articular features [2].

Among those extra-articular features are cardiovascular diseases, including pericarditis, cardiomyopathy, myocarditis, cardiac amyloidosis, coronary vasculitis, arrhythmias, valve diseases and, most importantly, congestive heart failure (CHF) and ischemic heart disease [3]. When compared with the general population, RA is associated with an increased mortality, the majority of which is originating from cardiovascular diseases. Patients with RA have an approximately two-fold higher incidence of CHF compared with the general population [4]. CHF is an independent risk factor for mortality in RA patients and is responsible for one in eight deaths of patients with RA [5].

Heart failure is the result of either systolic or diastolic dysfunction or both; left ventricular diastolic dysfunction (LVDD) encompasses mechanical abnormalities involving decreased distensibility, impaired relaxation, and abnormal diastolic filling of the left ventricle, irrespective of the ejection fraction [6]. Diastolic dysfunction has been also associated with diabetes mellitus, coronary artery disease, hypertension, and obesity [7].

The importance of diastolic dysfunction lies in the fact that it may serve as a precursor to systolic and diastolic...
CHF and also may cause morbidity and mortality on its own. It was reported that a number of patients with RA in whom no clinical cardiac abnormalities could be detected having diastolic dysfunction as detected by echocardiography suggests a subclinical myocardial involvement [8].

Diastolic dysfunction is an echocardiographic diagnosis made via transthoracic echocardiography, and cannot be made clinically [9]. Doppler echocardiography is a sensitive and noninvasive method of detecting cardiac abnormalities and systolic and/or diastolic function. Early identification of diastolic dysfunction in asymptomatic patients by echocardiography may provide an opportunity to manage the underlying etiology appropriately to prevent its progression to diastolic heart failure [10].

The higher incidence of CHF in RA necessitates the research of its precursor forms and preclinical assessment, and therefore the importance of studying diastolic dysfunction in patients with RA. The aim of this study was to determine the prevalence of LVDD in patients with RA with no history of heart diseases, and to study its association with other RA disease parameters.

**Patients and methods**

**Patients**
This is a cross-sectional study conducted on 75 RA patients who fulfilled the 2010 American College of Rheumatology and European League Against Rheumatism classification criteria for RA [11]. The patients were attending the Rheumatology Outpatient Clinic at Beni-Suef University Hospital, Egypt. Their age ranged from 20 to 45 years and disease duration ranged from 1 to 21 years. The patients were matched by age and sex to 38 healthy participants who served as a control group. The patients were studied from February 2018 through December 2018. The study was carried out with the approval of local ethics committee and in accordance with the national law and the Helsinki Declaration of 1975. Informed consent was obtained from all patients.

**Exclusion criteria**
None of the patients included in this study had evidence of cardiac disease as assessed by history, physical examination, and standard 12-lead ECG. They had no evidence of hypertension, ischemic heart disease, rheumatic heart disease, or any valvular heart disease, ventricular hypertrophy or pathological Q wave or arrhythmia on ECG. Other diseases like diabetes mellitus, renal insufficiency, hyperlipidemia, smoking, pregnancy, obesity (BMI ≥ 30) had been also excluded.

**Clinical evaluation**
All patients were subjected to full medical history taking and clinical examination. Each patient underwent clinical examination by a rheumatologist and cardiac assessment by a cardiologist. Weight and height were also determined to calculate BMI. Pain intensity was assessed using visual analog scale [12]. Joint tenderness was performed using Ritchie Articular index [13].

**Rheumatoid arthritis activity**
Current RA disease activity was measured using 28 Joint Disease Activity Score (DAS28) [14]. DAS28 is a composite score that consists of swollen and tender joint counts (0–28), erythrocyte sedimentation rate, and patient-assessed global score (0–100). A score above 5.1 means high disease activity, whereas a score below 3.2 indicates low disease activity.

**Rheumatoid arthritis disability**
Assessment of RA disability was done using the Arabic Version of the Health Assessment Questionnaire Disability Index [15].

**Investigations**
Complete blood count, first hour erythrocyte sedimentation rate (Westergren) [16], C-reactive protein, serum aspartate aminotransferase and alanine aminotransferase, serum creatinine and blood urea, rheumatoid factor by latex fixation test, anticyclic citrullinated peptide antibodies, cholesterol, high-density lipoprotein, low-density lipoprotein, fasting and postprandial blood sugar, chest radiography and hand radiography were done for all patients.

**ECG**
ECG was done to all patients and controls to exclude arrhythmias, chamber enlargement, and pathological Q wave, S-T and T wave changes, and QRS complex.

**Echocardiography and Doppler ultrasound**
The above tests were performed for all patients and controls according to the recommendations of the American Society of Echocardiography [17]. Echocardiography was performed by a trained cardiologist who was blinded to the clinical status of both groups and used the same echocardiographic instrument throughout the study. Echocardiography was performed to assess the flow pattern of the heart valves. All M-mode, two-dimensional Doppler
echocardiography measurements were averaged from at least three consecutive cardiac cycles. Assessment of the following parameters was done:

1. The pericardial fluid and thickness.
2. Chamber dimensions.
3. Systolic parameters of the left ventricle such as the left ventricular end systolic diameter, left ventricular end diastolic diameter, and ejection fraction were calculated using the M-Mode by assessment of fractional shortening, left ventricular posterior wall thickness, and septal wall thickness.
4. Diastolic parameters of the left ventricle such as peak early transmitial filling velocity (E wave in m/s), peak atrial filling velocity or late transmitial filling velocity (A wave in m/s), E/A ratio (usually >1 in young normal participants), E acceleration time, E deceleration time and E duration (in ms), A acceleration time, and deceleration time (in ms).

According to the E/A ratio and the deceleration time, the diastolic dysfunction was categorized into four categories [18]:

1. Grade I diastolic dysfunction (mild): impaired relaxation.
2. Grade II diastolic dysfunction (moderate): pseudonormalization.
3. Grade III diastolic dysfunction (severe, reversible): reversible restrictive pattern.
4. Grade IV diastolic dysfunction (severe, irreversible): irreversible restrictive pattern.

Statistical analysis
Data were analyzed by the statistical package for the social sciences (version 20.0 for Windows, SPSS Inc., Chicago, IL). Differences in frequencies were analyzed by Fisher’s exact test as appropriate. Student’s t-test was used to compare the difference between two group means in interval and ordinal variables. Associations between interval, ordinal, and dichotomous variables were tested by Pearson’s product moment correlation coefficients (r). Two-tailed tests were used throughout, with statistical significance set at the conventional 95% level.

Results
Demographic data and clinical features
Among the 75 studied patients, there were 58 (77.3%) women and 17 (22.7%) males. The mean age of RA patients was 33.4±7.5 (ranging from 20 to 45 years), the mean duration of illness was 7.2±5.7 (ranging from 1–21 years) with 72% seropositive for rheumatoid factor and 20% seropositive for anticyclic citrullinated peptide antibody. The mean DAS28 was 3.8±1.2 (ranging from 2.1–5.6), whereas the mean Health Assessment Questionnaire score was 0.97±0.7 (ranging from 0.12 to 2.87) (Table 1). At the time of the study, 36 (48%) patients were receiving methotrexate, 30 (40%) patients were on antimalarials, and 14 (18.7%) patients were receiving corticosteroids, whereas 12 (16%) patients were on biologic therapy. Combination between methotrexate and antimalarials was the most common, being detected in 23 (30.7%) patients.

Among the 38 healthy controls, there were nine (23.7%) men and 29 (76.3%) women; their age ranged from 20 to 45 years with a mean of 32.7±7.8 years. Both patient and control groups were matched for age and sex.

Prevalence of diastolic dysfunction in rheumatoid arthritis patients and controls
Diastolic dysfunction was significantly more common in the RA group being detected in 28 (37.3%) patients compared with four (10.5%) healthy participants in the control group (P<0.05). Among the 37.3% RA patients diagnosed with diastolic dysfunction, 18 (24%) patients had mild diastolic dysfunction with the remaining 10 (13.3%) having moderate diastolic dysfunction. However, in the control group, four (10.5%) patients only had mild diastolic dysfunction with no reported cases of moderate or severe diastolic dysfunction.

Our finding of increased prevalence of diastolic dysfunction in RA patients was further supported by other echocardiographic findings. RA patients had a significantly higher left atrium diameter compared with non-RA participants (P<0.01). The E wave

Table 1 Disease characteristics of rheumatoid arthritis patients

|                  | Range    | Mean±SD |
|------------------|----------|---------|
| Age              | 20–45    | 33.4±7.5|
| Disease duration | 1–21     | 7.2±5.7 |
| Age at onset     |          |         |
| 10–19            | 9 (18)   |         |
| 20–29            | 23 (46)  |         |
| 30–39            | 17 (34)  |         |
| 40–49            | 1 (2)    |         |
| DAS28            | 2.1–5.6  | 3.8±1.2 |
| HAQ              | 0.12–2.87| 0.97±0.7|

DAS28, 28 Joint Disease Activity Score; HAQ, Health Assessment Questionnaire.
and E/A ratio were both significantly lower in the RA group than the control group (\( P < 0.01 \)). In addition, 10 (13.3\%) of the RA patients had valvular affection in the form of mitral regurgitation, whereas none of the control group had any (Table 2).

### Table 2 Echocardiographic findings in rheumatoid arthritis patients and controls

| Patients (n=75) | Control (n=38) | \( P \) value |
|---------------|---------------|----------------|
| Left atrium diameter (cm) | 3.6±0.2 | 3.1±0.2 | 0.01* |
| LVEDD (cm) | 4.5±0.4 | 4.7±0.3 | 0.63 |
| LVEF (%) | 66.8±4.1 | 66.2±3.9 | 0.83 |
| E wave (m/s) | 0.6±0.4 | 0.8±0.4 | 0.003** |
| A wave (m/s) | 0.7±0.3 | 0.6±0.3 | 0.61 |
| E/A ratio | 1.1±0.4 | 1.4±0.5 | 0.002* |
| Valve affection [n (%)] | | | |
| Yes | 10 (13.3) | 0 (0) | 0.05** |
| No | 65 (86.7) | 38 (100) | |

LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction. *\( P < 0.05 \), significant difference. **\( P < 0.01 \), significant difference.

### Table 3 Correlations between diastolic dysfunction in rheumatoid arthritis patients with different disease characteristics

| Diastolic dysfunction | \( r \) | \( P \) |
|----------------------|--------|--------|
| Age (years) | 0.12 | 0.55 |
| Age at onset | 0.03 | 0.88 |
| Sex | 0.08 | 0.68 |
| BMI | 0.18 | 0.32 |
| Disease duration | 0.41* | 0.01 |
| Articular index | 0.06 | 0.74 |
| Swollen joints | 0.17 | 0.35 |
| DAS28 | 0.43* | 0.01 |
| HAQ | 0.09 | 0.62 |
| Methotrexate | 0.34 | 0.06 |

DAS28, 28 Joint Disease Activity Score; HAQ, Health Assessment Questionnaire. *\( P < 0.05 \), significant difference.

### Table 4 Diastolic dysfunction in rheumatoid arthritis patients with different grades of disease activity and disability

| Total | DD [n (%)] | \( P \) value |
|-------|------------|----------------|
| DAS28 | | |
| Mild | 30 | 3 (10) | 0.001** |
| Moderate | 33 | 15 (45.4) | |
| Severe | 12 | 10 (83.3) | |
| HAQ | | |
| Mild | 34 | 14 (41.2) | 0.6 |
| Moderate | 38 | 14 (36.8) | |
| Severe | 3 | 0 (0) | |

DD, diastolic dysfunction; DAS28, 28 Joint Disease Activity Score; HAQ, Health Assessment Questionnaire. **\( P < 0.01 \), significant difference.

Correlation between diastolic dysfunction and rheumatoid arthritis disease parameters

The presence of diastolic dysfunction in RA patients was statistically significantly positively correlated with disease duration (\( r=0.41, P<0.05 \)) and disease activity (\( r=0.43, P<0.05 \)) (Table 3). The presence of diastolic dysfunction was statistically significantly higher in patients with severe and moderate disease activity than those with mild activity (\( P<0.05 \)). However, the difference between different grades of disease disability regarding the presence of diastolic dysfunction was statistically insignificant (Table 4).

### Discussion

Seventy-five Egyptian RA patients satisfying the 2010 American College of Rheumatology and European League against Rheumatism classification criteria for RA [11] and 38 controls were recruited for this study. Diagnosis of LVDD was based on Doppler echocardiography. The aim of the study was to evaluate the LVDD as an early predictor of asymptomatic cardiac involvement in patients with RA detected by Doppler echocardiography and to correlate diastolic function in those patients with different RA disease characteristics.

The main limitation of this study was the nature of a cross-sectional study which may limit the types of conclusions that can be drawn, as these observations are associations and not necessarily causal.

In our study, diastolic dysfunction was detected in 28 (37.2\%) of RA patients and in four (10.5\%) of the control group, in accordance with the study by Montecucco et al. [8], in which impairment of diastolic dysfunction was reported in 38.9\% of RA and in 25.9\% of controls in a study of 54 RA patients and 54 healthy participants [8]. Another study by Crowsen et al. [19] had determined the presence of diastolic dysfunction in 26.5\% and in 21.7\% of non-RA.

Several studies have reported an association between RA and features of impaired diastolic ventricular function, as reviewed by Giles et al. [20] using Doppler determination of transmitral flow velocity Alterations of the E/A ratio
have been demonstrated for RA patients compared with controls in several studies [8,21–26]. Similar to our study, many studies have confirmed the high presence of diastolic dysfunction in RA patients and lower impairment of E/A ratio compared with the control group. Arslan et al. [27] had conducted a study on 52 RA patients and 47 normal persons to assess the left ventricular diastolic function by assessment of transmitral flow and tissue Doppler imaging, and they observed that E/A ratio was significantly statistically lower in RA patients than in controls. Another study conducted by Udayakumar et al. [28] studied 45 RA patients and confirmed a high frequency of LVDD in patients with RA without evident cardiovascular disease when compared with controls.

In contrast, other studies showed no statistically significant difference between RA patients and control population as regards the prevalence of diastolic dysfunction [26,29–31].

The main explanation of this variation in diastolic dysfunction presence might be due to the fact that some of the studies perhaps use different techniques to assess diastolic dysfunction. Observer bias should be considered as most studies did not specify if the echocardiography was blinded or not. Several factors may confound the reported findings in the selected studies. The E/A ratio was by far the most frequently used echocardiographic parameter to assess diastolic function in the studies. Hence, we used this variable in our pooled analysis. In clinical practice, assessment of diastolic function is based on a combination of parameters such as propagation velocity and intraventricular dispersion of E wave velocity. This may limit the generalization of our findings.

In addition, some studies did not exclude associated cardiac diseases in their studies, whereas others did. Notably, all of our RA patients have no symptoms or signs suggestive of any cardiac disease. Isolated diastolic dysfunction has been previously associated with a marked increase in mortality in the general population [32,33]. Hence, the increased prevalence of isolated diastolic dysfunction in RA may have implications on excess mortality in RA patients [34]. For this reason, primary diastolic dysfunction is an important cause of heart failure, as it is often a silent alteration preceding systolic dysfunction. So, knowledge of this complication in patients with RA without clinically evident cardiac disease may be important to improve patient survival. In our study, duration of RA disease was strongly associated with diastolic dysfunction, although, some other studies did not suggest such a link [35]. Similar to our finding, a correlation between diastolic dysfunction and disease duration in patients with RA had also been reported in other study [36]. Sonkusare et al. [37] studied 35 RA patients versus 25 controls and they concluded that diastolic dysfunction may develop especially in RA patients with disease duration of more than 5 years. This actually may reflect a chronic subclinical myocardial process leading to impairment of myocardial function [34].

Our study showed a significant positive correlation between LVDD and disease activity assessed by the DAS28 score. This finding was in agreement with the study of Carlos et al. [38] who also used DAS28 in assessment of activity. Another study by Targosinska-Stepniak et al. [39] reported a significant correlation between diastolic dysfunction and the activity of RA. This could be explained by the fact that active disease may be associated with interstitial fibrosis and diminished left ventricular compliance that ends in diastolic dysfunction.

Conclusion

This study highlights that RA patients are more susceptible to cardiac complications more than normal patients. Therefore, routine screening of RA patients with Doppler echocardiography may detect subclinical cardiac involvement and corrective measures could be done before clinically evident heart failure ensues. Knowledge of this complication in patients with RA without clinically evident cardiac disease may be important to improve patient survival.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Ferro F, Elefante E, Luciano N, Talarico R, Todoerti M. One year in review 2017: novelities in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2017; 35:721–734.
2. Turesson C, O’Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002; 29:62–67.
3. Voiskuyl E. The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology 2006; 45:4–7.
4. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986; 13:841–845.
5. Mutru O, Laakso M, Isomäki H, Koota K. Cardiovascular mortality in patients with rheumatoid arthritis. Cardiology 1989; 76:71–77.
6. Fukuta H, Little WC. Diagnosis of diastolic heart failure. Curr Cardiol Rep 2007; 9:224–228.
Diastolic dysfunction in patients with RA  Ghaleb et al.  153

7 Aichong N, Wahi S, Marwick TH. Evolution and outcome of diastolic dysfunction. Heart 2009; 95:813–818.
8 Montecucco C, Gobbi G, Perlini S, Rossi S, Grandi AM, Caporali R, et al. Impaired diastolic function in active rheumatoid arthritis: relationship with disease duration. Clin Exp Rheumatol 1997; 17:407–412.
9 Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part I. Diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105:1387–1393.
10 Oh JK, Hatle L, Tajik AJ, Little WC. Diastolic heart failure can be diagnosed by comprehensive two-dimensional and doppler echocardiography. J Am Coll Cardiol 2006; 47:3.
11 Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569–2581.
12 McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med 1988; 18:1007–1019.
13 Ritchie DM, Boyle JA, McInnes JM, Jasan MK, Dalakos TG, Grieveson P, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with RA. Q J Med 1968; 37:393–398.
14 Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38:44–48.
15 Fries JF, Spitz P, Khairez RH. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23:137–145.
16 Westergren A. Diagnostic tests: the erythrocyte sedimentation rate range and limitations of the technique. Triangle 1957; 3:20–25.
17 Hahn RT, Abraham T, Adams MS, Bruce CJ, Glase KE, Lang RM, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination: recommendations from the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. J Am Soc Echocardiogr 2013; 26:921–964.
18 Yaney CW, Jessup M, Bozkurt B, Butler J, Casey DE, Dzurman MH, et al. ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62:1495–1539.
19 Crowson CS, Myasoedova E, Davis JM, Roger VL, Karon BL, Borgeson D, et al. Use of B-type natriuretic peptide as a screening tool for left ventricular diastolic dysfunction in rheumatoid arthritis patients without clinical cardiovascular disease. Arthritis Care Res 2011; 63:729–734.
20 Giles JT, Fernandes V, Lima JA, Bathon JM. Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. Arthritis Res Ther 2005; 7:195–207.
21 Alpaslan M, Onrat E, Evcik D. Doppler echocardiographic evaluation of ventricular function in patients with rheumatoid arthritis. Clin Rheumatol 2003; 22:84–88.
22 Corrao S, Salli L, Amone S, Scaglione R, Pinto A, Licata G. Echo-Doppler left ventricular filling abnormalities in patients with rheumatoid arthritis without clinically evident cardiovascular disease. Eur J Clin Invest 1996; 26:293–297.
23 Kremers HM, Crowson CS, Gabriel SE. Epidemiology Project: a unique resource for research in the rheumatic diseases. Rheum Dis Clin North Am 2004; 30:819–834.
24 Levendoglu F, Temizhan A, Ugurolu H, Ozdemir A, Yazici M. Ventricular function abnormalities in active rheumatoid arthritis: a Doppler echocardiographic study. Rheumatol Int 2004; 24: 141–146.
25 Yavasoglu I, Senturk T, Onbasili A. Diastolic dysfunction in rheumatoid arthritis and duration of disease. Rheumatol Int 2008; 29:113–114.
26 Wlosowska M, Syypula S, Kowalik I. Echocardiographic findings, 24-hour electrocardiographic Holter monitoring in patients with rheumatoid arthritis according to Steinbrocker’s criteria, functional index, value of Waaler-Rose titre and duration of disease. Clin Rheumatol 1998; 17:369–377.
27 Arslan S, Bozkurt E, Sari RA, Erol MK. Diastolic function abnormalities in active rheumatoid arthritis evaluation by conventional Doppler and tissue Doppler: relation with duration of disease. Clin Rheumatol 2006; 25:294–299.
28 Udayakumar N, Venkatesan S, Rajendran C. Diastolic function abnormalities in rheumatoid arthritis: relation with duration of disease. Singapore Med J 2007; 48:537–542.
29 Acar G, Sayarioglu M, Akay S, Sokmen A, Sokmen G, Yalcintas S, et al. Evaluation of atrial electromechanical delay and left atrial mechanical functions in patients with rheumatoid arthritis. Turk Kardiyol Dern Ars 2009; 37:447–453.
30 Rudominer RL, Roman MJ, Devereux RB, Paget SA, Schwartz JE, Lockshin MD, et al. Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis Rheum 2009; 60:22–29.
31 Abdul Muzz AM, MohdShahrir MS, Sazliyana S, Oteh M, Shamsul AS, Hussein H. A cross-sectional study of diastolic dysfunction in rheumatoid arthritis and its association with disease activity. Int J Rheum Dis 2011; 14:18–30.
32 Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289:194–202.
33 Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nikomo VT, et al. Systolic and diastolic heart failure in the community. JAMA 2006; 296:2209–2216.
34 Liang KP, Myasoedova E, Crowson CS, Davis JM, Roger VL, Karon BL, et al. Increased prevalence of diastolic dysfunction in rheumatoid arthritis. Ann Rheum Dis 2010; 69:1665–1670.
35 Aslam F, Bandeali SJ, Khan NA, Alam M. Diastolic dysfunction in rheumatoid arthritis: a meta-analysis and systematic review. Arthritis Care Res 2013; 65:534–543.
36 DiFranco M, Paradiso M, Mammarella A, Paolletti V, Labbadia G, Coppolletti L, et al. Diastolic function abnormalities in rheumatoid arthritis: evaluation by echo Doppler transmitial flow and pulmonary venous flow. Relation with duration of disease. Ann Rheum Dis 2000; 59:227–229.
37 Sonkusare R, Nelson S. Diastolic dysfunction in rheumatoid arthritis. J Evol Med Dent Sci 2014; 3:4560–4568.
38 Carlos E, Alexander L, Mithun P, Jose N, Debabrata M. Prevalence and predictors of left ventricular diastolic dysfunction in a Hispanic patient population. Int J Angiol 2013; 22:229–234.
39 Targonska-Stepniak B, Biskup M, Biskup W, Majdan M. Diastolic dysfunction in rheumatoid arthritis patients with low disease activity. Clin Rheumatol 2018; DOI: 10.1007/s10067-018-4369. [Epub ahead of print].